Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Clinical Trials Transparency: EMA Delay Gives Industry Initiative More Time To Take Root

This article was originally published in The Pink Sheet Daily

Executive Summary

EMA’s plans for access to clinical trials data not set to be ready until well into 2014.


Related Content

EMA's Walks Fine Line On How It Will Publish Clinical Study Reports
Clinical Data Transparency Would Counter-Balance Off-Label Promotion – NEJM
Confidentiality Definition Comes Closer After AbbVie Drops EMA Cases
BIO’s Clinical Trial Disclosure Policy Allows Researchers Access To Data On Approved Medicines
JAMA Studies Provide More Ammunition For Trial Disclosure Reformers
J&J’s Clinical Data Disclosure Strategy Focuses On Collaboration With Yale University Group
EMA Birth Control Safety Review Shows PRAC’s Clout, Concern About Newer Products
European Generics Applications Fall, As EMA’s Interim Report Hopes To Herald Funding Renewal
Mediator Is Tip Of EU Parliament's Probe Into EMA; Funding Held In Balance
Pharmacovigilance Feeds EMA’s Transparency Drive


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts